Keyword Connections

amikacin

Journals

1

1 Frontiers in microbiology

Research Groups

0

No Research Group Connected

Bibliographies

32

1 Differential Activity of the Combination of Vancomycin and Amikacin on Planktonic vs. Biofilm-Growing Bacteria in a Hollow Fiber Infection Model.

2 study of the antimicrobial effect of amikacin encapsulated in mesoporous silica nanoparticles against pseudomonas aeruginosa and staphylococcus aureus

3 efeito da oxigenação hiperbárica em lesão ototóxica produzida pela amicacina em cobaias the effects of hyperbaric oxygen therapy upon ototoxic injuries produced by amikacin in guinea pigs

4 influence of doxorubicin on adhesive properties of e.coli

5 Efficacy of intraventricular amikacin treatment in pan-resistant Pseudomonas aeruginosa postsurgical meningitis

6 Defining the potency of amikacin against Escherichia coli, Klebsiella pneumoniae, Pseudomonas aeruginosa, and Acinetobacter baumannii derived from Chinese hospitals using CLSI and inhalation-based breakpoints

7 High-dose amikacin for achieving serum target levels in critically ill elderly patients

8 Once-daily intramuscular amikacin for outpatient treatment of lower urinary tract infections caused by extended-spectrum β-lactamase-producing Escherichia coli in children

9 Efficacy of intraventricular amikacin treatment in pan-resistant Pseudomonas aeruginosa postsurgical meningitis

10 Defining the potency of amikacin against Escherichia coli, Klebsiella pneumoniae, Pseudomonas aeruginosa, and Acinetobacter baumannii derived from Chinese hospitals using CLSI and inhalation-based breakpoints

11 High-dose amikacin for achieving serum target levels in critically ill elderly patients

12 Once-daily intramuscular amikacin for outpatient treatment of lower urinary tract infections caused by extended-spectrum β-lactamase-producing Escherichia coli in children

13 Development and validation of a pre-column derivatization HPLC method for the assay of amikacin sulfate in pure and parenteral dosage forms

14 Optimization and Designing of Amikacin-loaded Poly D, L-Lactide-co-glycolide Nanoparticles for Effective and Sustained Drug Delivery.

15 Optimization and Designing of Amikacin-loaded Poly d, l-Lactide-co-glycolide Nanoparticles for Effective and Sustained Drug Delivery

16 Simultaneous Quantification of Ethambutol and Amikacin in Human Sputum by HPLC-MS/MS

17 Sequential analysis as a tool for detection of amikacin ototoxicity in the treatment of multidrug-resistant tuberculosis.

18 Randomized Trial of Cefepime Monotherapy or Cefepime in Combination with Amikacin as Empirical Therapy for Febrile Neutropenia

19 Monotherapy with piperacillin/tazobactam versus combination therapy with ceftazidime plus amikacin as an empiric therapy for fever in neutropenic cancer patients

20 A multicenter, double-blind, placebo-controlled trial comparing piperacillin-tazobactam with and without amikacin as empiric therapy for febrile neutropenia

21 Monotherapy with piperacillin/tazobactam versus combination therapy with ceftazidime plus amikacin as an empiric therapy for fever in neutropenic cancer patients

22 adverse drug reaction following injection of amikacin sulphate in a cluster of preterm newborns

23 a novel luminol-based chemiluminescence method for the determination of amikacin sulfate in serum by using trivalent copper-periodate complex

24 tobramycin and amikacin delay adhesion and microcolony formation in pseudomonas aeruginosa cystic fibrosis isolates

25 Amikacin use and therapeutic drug monitoring in adults: do dose regimens and drug exposures affect either outcome or adverse events? A systematic review

26 Therapeutic drug monitoring of amikacin in septic patients

27 Higher than recommended amikacin loading doses achieve pharmacokinetic targets without associated toxicity

28 Revisiting the loading dose of amikacin for patients with severe sepsis and septic shock

29 Determinants of amikacin first peak concentration in critically ill patients

30 Predictors of insufficient amikacin peak concentration in critically ill patients receiving a 25 mg/kg total body weight regimen

31 Revisiting the loading dose of amikacin for patients with severe sepsis and septic shock - Critical Care

32 Amikacin use and therapeutic drug monitoring in adults: do dose regimens and drug exposures affect either outcome or adverse events? A systematic review